<!DOCTYPE HTML PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html lang="en-US" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<!-- BEGIN: ftx_abs.tpl -->

<!-- BEGIN: journal-article.html-main.tpl -->



	<title>Wiley InterScience :: Article Full Text HTML</title>
	

	
	
	
	

 	
	
	<!-- JavaScript for Linking mechanism -->
	
	
	
	<!-- JavaScript for Embedded images -->
	
	

	<!-- SmartSource 8 -->
	<meta name="WT.sv" content="">
	<meta name="DCS.dcsuri" content="%2Fcgi-bin%2Ffulltext%2F%2FHTMLSTART">
	<meta name="DCS.dcsqry" content="">
	<meta name="DCS.dcsdat" content="1254283162583"><meta name="DCSext.SiteCd" content="DEV_InterScience">

<link rel="stylesheet" type="text/css" href="index_4.css" media="all">
</head>
<body id="wileyinterscience" bgcolor="#ffffff">
<a id="pageTop" name="pageTop"></a>
<a id="top" name="top"></a>

<div id="contentFrame" class="journalArticleMain">
	<!-- BEGIN: main column -->
	<div class="mainCol">

		<!-- BEGIN: intro area -->
		<div id="intro" class="area" style="padding-left: 10px ! important;">

			<div class="item">
				<table border="0" cellpadding="0" cellspacing="0">
					<tbody><tr valign="top">
						<td width="100%">

							<!-- BEGIN: branding area -->
							<div class="banner">
								
								
								
								
<!-- BEGIN: product banner  -->

<table bgcolor="#eeeeee" border="0" cellpadding="0" cellspacing="0" width="100%">
	<tbody><tr>
	<td><img src="bannerforeground.jpg" alt="" border="0"></td>
	</tr>
</tbody></table>
<!-- END: product banner  -->


							</div>
							<!-- END: branding area -->

							<table border="0" cellpadding="0" cellspacing="0">
								<tbody><tr valign="top">
									<td width="100%">
										<!-- BEGIN: item info area -->
										<div class="info">
											<h2><a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/journal/121548564/home" target="_top">British Journal of Pharmacology</a></h2>
											<p style="margin-top: 0.6em;">
										
											
												<a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/rss/journal/121548564">
													<img src="rss_feed.gif" alt="RSS feed for British Journal of Pharmacology" title="RSS feed for British Journal of Pharmacology" align="absbottom" border="0">
												</a>
												<span class="text"><a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/help?page=HELP_syndication#RSS">What is RSS?</a></span>
											
										
											</p>
											
											
											<h6><a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/journal/122205689/issue" target="_top">Volume 143, Issue 8</a>, Pages 933-937</h6>
											
											<p><strong>Published Online:</strong> 17 Feb 2009</p>

											

											


											
																						<div style="padding-top: 10px;"><a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/journal/121548564/home" title="Go to the homepage for this journal to access trials, sample copies, editorial and author information, news, and more." target="_top"><img src="link.journal.homepage.gif" alt="Journal Homepage Link" border="0" height="46" width="270"></a></div>
										</div>
										<!-- END: item info area -->
									</td>

									<td width="100">
										<!-- email / print tools -->
                                        <div class="tools"><img src="icons.email-print.gif" alt="E-Mail and Print Toolbar" usemap="#map_email-print" border="0" height="20" width="90"><map name="map_email-print" id="map_email-print"><area shape="rect" coords="2,4,44,16" href="javascript:mailTool(122205701,%20'',%20'',%20'currentlink','htmlfull');" id="email" alt="E-Mail" title="E-Mail This Page"><area shape="rect" coords="48,4,89,16" href="javascript:print();" id="print" alt="Print" title="Print This Page"></map></div>

										<!-- published for the society of ... -->
										<div class="published">
											
										</div>
									</td>
								</tr>
							</tbody></table>
						</td>
						<td>
							<div class="sideCol">
								<!-- BEGIN: search-combined.tpl -->
<table border="0" cellpadding="0" cellspacing="0">
	<!-- Show ADS Search -->
	

	<tbody><tr>
		<td class="BGpowderblue">
			<div id="searchBox">
				<div id="searchTitles" class="item">
					<form action="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/journal/titlesearch" method="post" id="searchTitles" name="searchTitles" target="_top">
						<fieldset>
							<!-- NOTE: this span must be here or else ie/win adds left padding when FIELDSET is used instead of DIV -->
							<span>
							<input name="query" value="" type="hidden">
							<input name="pagenum" value="1" type="hidden">
							</span>
						</fieldset>
					</form>
					<form action="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/search/allsearch" method="get" id="searchArticlesForm" name="allContentSearchForm" target="_top">
						<fieldset>
							<!-- NOTE: this span must be here or else ie/win adds left padding when FIELDSET is used instead of DIV -->
							<span>
								<input name="mode" value="quicksearch" type="hidden">
								<input name="WISindexid1" value="WISall" type="hidden">
								<input name="WISsearch1" value="" type="hidden">
							</span>
						</fieldset>
					</form>
					<form name="formSelector" action="javascript:selectAndSubmit();" target="_top">
						<fieldset>
							<table class="dataTable" style="padding-bottom: 0.2em;" border="0" cellpadding="0" cellspacing="0">
								<tbody><tr>
									<td rowspan="2" valign="top"><h3><img src="txt.search.gif" alt="Search" border="0" height="16" vspace="3" width="49"></h3></td>
									<td><input name="whichForm" value="allContentSearch" checked="checked" type="radio"><label for="allContent">All Content</label></td>
								</tr>
								<tr><td><input name="whichForm" value="searchTitles" type="radio"><label for="pubTitle">Publication Titles</label></td></tr>
								</tbody>
							</table>
							<div></div><table class="dataTable" borders="0" cellpadding="0" cellspacing="0">
								<tbody><tr>
								<td>
									<label for="articleKeywords" class="invisible"><span class="txt">Enter words or phrases</span><br></label>
									<input name="terms" id="articleKeywords" value="" style="width: 130px;" size="12" type="text">
								</td>
								<td>
									<a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/fulltext/122205701/void%280%29;" onclick="selectAndSubmit();return false;"><img type="image" src="but.go.gif" alt="Go" border="0"></a>
								</td>
								</tr></tbody>
							</table>
						</fieldset>
						<ul class="noBullet" style="padding-bottom: 0pt;">
						<li><a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/search/allsearch" target="_top">Advanced Search</a></li>
						<li><a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/crossref.html">CrossRef / Google Search</a></li>
						<li><a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/stasa/search.html">Acronym Finder</a></li>
						</ul>
					</form>
				</div>
			</div>
		</td>
	</tr>
</tbody></table>
<!-- END: search-combined.tpl -->

							</div>
						</td>
					</tr>
				</tbody></table>
			</div>
		</div>
		<!-- END: intro area -->


		<!-- BEGIN: content -->
		<div id="content" class="area">

			<div class="subContent">
				<div class="line"><img src="dot.ccc.gif" alt="" border="0" height="1" width="100%"></div>

				<!-- issue nav -->
				<table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr>
					<td><p class="issueNav"><nobr>  <span>&lt;</span> <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/fulltext/122205694/HTMLSTART" target="_top">Previous Article</a>   &nbsp;|&nbsp;    <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/fulltext/122205695/HTMLSTART" target="_top">Next Article</a> <span>&gt;</span></nobr></p></td>
				</tr></tbody></table>

				<!-- BEGIN: abstract header-->
				<div class="item">
					<p><img src="icon.bullet.orange_001.gif" alt="" border="0" height="9" width="9"> <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/savedarticleform?ID=122205701&amp;path_ok=/cgi-bin/fulltext/122205701/HTMLSTART" class="linkMore" target="_top">Save Article to My Profile</a>
					<!-- Link to Citation Export -->
					&nbsp;&nbsp;&nbsp;&nbsp;
					<img src="icon.bullet.orange_001.gif" alt="" border="0" height="9" width="9"> <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/tools/citex?clienttype=1&amp;subtype=1&amp;mode=1&amp;version=1&amp;id=122205701&amp;redirect=/cgi-bin/fulltext/122205701/HTMLSTART" class="linkMore" target="_top">Download Citation</a>
					</p><p>
						<a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/abstract/122205701/ABSTRACT" target="_top">Abstract</a>
						
						&nbsp;|&nbsp; <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/abstract/122205701/REFERENCES" target="_top">References</a>
						
						&nbsp;|&nbsp; Full Text: <strong>HTML</strong>

, <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/fulltext/122205701/PDFSTART" target="_top">PDF</a> (174k)
					
						
						
					</p><div class="txt" style="text-align: right;"><a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/fulltext/122205701/HTMLSTARTW" class="linkMore" target="_top">View Full Width</a></div>
				</div>
				<!-- END: abstract header-->

				<div class="line"><img src="dot.ccc.gif" alt="" border="0" height="2" width="100%"></div>
			</div>

			<!-- BEGIN: prerendered content -->
			<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr>
				<td width="10"><div class="spacer"><img src="dot.clear.gif" alt="" border="0" height="1" width="10"></div></td>
				<td>
					<div class="prerendered">

					<!--Revision: 21754 --><div xmlns="http://www.w3.org/1999/xhtml" class="article" id="top">
<a class="invisible-anchor" name="top">&nbsp;</a><div class="header"><div class="titlegroup"><div class="title-document">GW9662, a potent antagonist of PPAR<span class="i">γ</span>, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR<span class="i">γ</span> agonist rosiglitazone, independently of PPAR<span class="i">γ</span> activation</div></div><div class="author-info"><span class="name"><span class="forenames">Jill M</span> <span class="surname">Seargent</span><sup><nobr>1</nobr></sup></span>, <span class="name"><span class="forenames">Elisabeth A</span> <span class="surname">Yates</span><sup><nobr>1</nobr></sup></span> &amp; <span class="name"><span class="forenames">Jason H</span> <span class="surname">Gill</span><sup><nobr>1</nobr></sup><a href="#c1"></a></span><div class="addresses"><span class="address">

<a class="invisible-anchor" name="a1">&nbsp;</a><span id="a1"><span class="number"><sup><nobr>1</nobr></sup></span>Cancer Research Unit, Tom Connor's Cancer Research Centre, University of Bradford, All Saints Road, Bradford BD7 1DP</span>
</span></div><div class="correspondence-address"><span class="correspondence-label">Correspondence to </span>
<a class="invisible-anchor" name="c1">&nbsp;</a><span id="c1">Cancer Research Unit, Tom Connor's Cancer Research Centre, University of Bradford, All Saints Road, Bradford BD7 1DP. E-mail: <a class="externallink" href="mailto:j.gill1@bradford.ac.uk">j.gill1@bradford.ac.uk</a></span></div></div><div class="header-footnotes"></div><div class="bpg40copyright">Copyright 2004 British Pharmacological Society</div></div>
<div class="keywords-block"><div class="keyword-title">KEYWORDS</div><div class="keywords">Breast cancer • GW9662 • peroxisome proliferator-activated receptor (PPAR) • PPAR<span class="i">γ</span> • rosiglitazone</div></div>
<div class="abstract-content" id="abstract">
<div class="summary"><div class="header_divide"><h1 class="abstract-title" id="Abstract">ABSTRACT</h1></div><table><tbody><tr><td><img src="sec_here_small.gif" alt="Abstract" title="Abstract" border="0"></td><td><a href="#ss1"><img src="sec_down_small.gif" alt="Introduction" title="Introduction" border="0"></a></td><td><a href="#ss2"><img src="sec_down_small.gif" alt="Methods" title="Methods" border="0"></a></td><td><a href="#ss3"><img src="sec_down_small.gif" alt="Results" title="Results" border="0"></a></td><td><a href="#ss4"><img src="sec_down_small.gif" alt="Discussion" title="Discussion" border="0"></a></td><td><a href="#ss5"><img src="sec_down_small.gif" alt="" title="" border="0"></a></td><td><a href="#ss6"><img src="sec_down_small.gif" alt="References" title="References" border="0"></a></td></tr></tbody></table>
<p class="para">Peroxisome proliferator-activated receptor gamma (PPAR<span class="i">γ</span>), a member of the nuclear receptor superfamily, is activated by several compounds, including the thiazolidinediones. In addition to being a therapeutic target for obesity, hypolipidaemia and diabetes, perturbation of PPAR<span class="i">γ</span> signalling is now believed to be a strategy for treatment of several cancers, including breast. Although differential expression of PPAR<span class="i">γ</span> is observed in tumours compared to normal tissues and PPAR<span class="i">γ</span> agonists have been shown to inhibit tumour cell growth and survival, the interdependence of these observations is unclear. This study demonstrated that the potent, irreversible and selective PPAR<span class="i">γ</span> antagonist GW9662 prevented activation of PPAR<span class="i">γ</span> and inhibited growth of human mammary tumour cell lines. Controversially, GW9662 prevented rosiglitazone-mediated PPAR<span class="i">γ</span> activation, but enhanced rather than reversed rosiglitazone-induced growth inhibition. As such, these data support the existence of PPAR<span class="i">γ</span>-independent pathways and question the central belief that PPAR<span class="i">γ</span> ligands mediate their anticancer effects <span class="i">via</span> activation of PPAR<span class="i">γ</span>.</p>
<p class="para"><span class="i">British Journal of Pharmacology</span> (2004) <span class="b">143</span>, 933–937. doi:<a class="externallink" target="_new" href="http://dx.doi.org.ejproxy.a-star.edu.sg/10.1038/sj.bjp.0705973">[DOI link]</a></p></div></div><hr align="left" size="1" width="25%"><div class="dates"><span class="history">
<p class="para">(Received May 6, 2004, Revised July 27, 2004, Accepted August 11, 2004)</p></span></div><div class="doi-block"><div class="doi-title">DIGITAL OBJECT IDENTIFIER (DOI)</div><span class="doi">10.1038/sj.bjp.0705973</span> <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/doiinfo.html" target="_new">About DOI</a></div><div class="body-content">
<a class="invisible-anchor" name="s1">&nbsp;</a>
<div class="body-content" id="s1">
<a class="invisible-anchor" name="ss1">&nbsp;</a>
<div class="subsection-level1" id="ss1">
<a class="invisible-anchor" name="h2">&nbsp;</a>
<h1 id="h2" class="h1-heading">Introduction</h1><table><tbody><tr><td><a href="#abstract"><img src="sec_up_small.gif" alt="Abstract" title="Abstract" border="0"></a></td><td><a href="#ss1"><img src="sec_here_small.gif" alt="Introduction" title="Introduction" border="0"></a></td><td><a href="#ss2"><img src="sec_down_small.gif" alt="Methods" title="Methods" border="0"></a></td><td><a href="#ss3"><img src="sec_down_small.gif" alt="Results" title="Results" border="0"></a></td><td><a href="#ss4"><img src="sec_down_small.gif" alt="Discussion" title="Discussion" border="0"></a></td><td><a href="#ss5"><img src="sec_down_small.gif" alt="" title="" border="0"></a></td><td><a href="#ss6"><img src="sec_down_small.gif" alt="References" title="References" border="0"></a></td></tr></tbody></table>
<p class="para">Activation of peroxisome proliferator-activated receptor (PPAR)<span class="i">γ</span> and regulation of gene transcription is a multistep process that involves ligand binding, heterodimerisation with retinoid X receptor (RXR), interaction with sequence-specific gene promoter elements (termed PPAR response elements (PPREs)), and recruitment of coactivators and other nuclear coregulatory proteins (<a href="#b9"><sup><nobr>Kliewer <span class="i">et al</span>., 2001</nobr></sup></a>; <a href="#b7"><sup><nobr>Gill &amp; Roberts, 2003</nobr></sup></a>). As well as being central to the regulation of lipid metabolism, PPAR<span class="i">γ</span> is now believed to have a role in tumorigenesis (<a href="#b16"><sup><nobr>Roberts-Thomson, 2000</nobr></sup></a>; <a href="#b7"><sup><nobr>Gill &amp; Roberts, 2003</nobr></sup></a>). In breast tissue, agonists of PPAR<span class="i">γ</span> have been shown to inhibit cell growth, reduce oestrogen production by adipose tissue, inhibit oestrogen receptor (ER) activity and play a role in tumour regression (<a href="#b1"><sup><nobr>Agarwal <span class="i">et al</span>., 2000</nobr></sup></a>; <a href="#b17"><sup><nobr>Rubin <span class="i">et al</span>., 2000</nobr></sup></a>; <a href="#b14"><sup><nobr>Pighetti <span class="i">et al</span>., 2001</nobr></sup></a>; <a href="#b19"><sup><nobr>Wang &amp; Kilgore, 2002</nobr></sup></a>; <a href="#b15"><sup><nobr>Qin <span class="i">et al</span>., 2003</nobr></sup></a>). Similarly, in cultured breast cells PPAR<span class="i">γ</span> agonists can induce extensive lipid accumulation and reduce clonogenic survival (<a href="#b5"><sup><nobr>Elstner <span class="i">et al</span>., 1998</nobr></sup></a>). As such, PPAR<span class="i">γ</span> agonists have been proposed as anticancer therapeutics for breast cancer, a theory currently being tested in clinical trials (<a href="#b2"><sup><nobr>Burstein <span class="i">et al</span>., 2003</nobr></sup></a>).</p>
<p class="para">Although the therapeutic potential of PPAR<span class="i">γ</span> agonists as anticancer agents is clearly evident, the role of PPAR<span class="i">γ</span> activation in the process and thus their mechanism of action remain unclear. For instance, no clear correlation is observed between the sensitivity of the MT breast cell line panel to PPAR<span class="i">γ</span> ligands and their PPAR<span class="i">γ</span> expression levels (<a href="#b11"><sup><nobr>Mueller <span class="i">et al</span>., 1998</nobr></sup></a>). Similarly, studies using murine embryonic stem cells and fibroblasts demonstrated the presence of PPAR<span class="i">γ</span>-independent pathways of growth inhibition by PPAR<span class="i">γ</span> agonists (<a href="#b12"><sup><nobr>Palakurthi <span class="i">et al</span>., 2001</nobr></sup></a>). This study sought to investigate whether PPAR<span class="i">γ</span> activation was central to the inhibition of human breast cancer cell growth induced by PPAR<span class="i">γ</span> ligands. Breast tumour cell growth and survival were assessed using the potent irreversible PPAR<span class="i">γ</span> selective antagonist 2-chloro-5-nitrobenzanilide (GW9662) in the presence and absence of the PPAR<span class="i">γ</span> agonist rosiglitazone. Furthermore, since PPAR<span class="i">γ</span> agonists have already shown clinical worth for other human diseases and are currently in clinical trials as anticancer agents (<a href="#b2"><sup><nobr>Burstein <span class="i">et al</span>., 2003</nobr></sup></a>), this study may have important implications for breast cancer therapy.</p></div>
<a class="invisible-anchor" name="ss2">&nbsp;</a>
<div class="subsection-level1" id="ss2">
<a class="invisible-anchor" name="h3">&nbsp;</a>
<h1 id="h3" class="h1-heading">Methods</h1><table><tbody><tr><td><a href="#abstract"><img src="sec_up_small.gif" alt="Abstract" title="Abstract" border="0"></a></td><td><a href="#ss1"><img src="sec_up_small.gif" alt="Introduction" title="Introduction" border="0"></a></td><td><a href="#ss2"><img src="sec_here_small.gif" alt="Methods" title="Methods" border="0"></a></td><td><a href="#ss3"><img src="sec_down_small.gif" alt="Results" title="Results" border="0"></a></td><td><a href="#ss4"><img src="sec_down_small.gif" alt="Discussion" title="Discussion" border="0"></a></td><td><a href="#ss5"><img src="sec_down_small.gif" alt="" title="" border="0"></a></td><td><a href="#ss6"><img src="sec_down_small.gif" alt="References" title="References" border="0"></a></td></tr></tbody></table>
<a class="invisible-anchor" name="ss2-1">&nbsp;</a>
<div class="subsection-level2" id="ss2-1">
<a class="invisible-anchor" name="h4">&nbsp;</a>
<h2 id="h4" class="h2-heading">Cell culture</h2>
<p class="para">Human breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-468) were obtained from the European Cell Culture Collection (ECACC). All cell lines were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 m<span class="smallcapitals">M L</span>-glutamine and 1 m<span class="smallcapitals">M</span> sodium pyruvate in a humidified 5% CO<sub><nobr>2</nobr></sub> atmosphere at 37°C. The media were changed every 3 days and the cells passaged <span class="i">via</span> trypsinisation before reaching confluency.</p></div>
<a class="invisible-anchor" name="ss2-2">&nbsp;</a>
<div class="subsection-level2" id="ss2-2">
<a class="invisible-anchor" name="h5">&nbsp;</a>
<h2 id="h5" class="h2-heading">Western blotting</h2>
<p class="para">Cells grown in monolayer were harvested at subconfluency, lysed and total protein isolated. Briefly, cells were scraped from the flask, lysed in RIPA buffer (150 m<span class="smallcapitals">M</span> NaCl, 50 m<span class="smallcapitals">M</span> Tris–HCl, pH 7.4, 5 m<span class="smallcapitals">M</span> EDTA, 1% NP40, 0.1% SDS, 1 m<span class="smallcapitals">M</span> phenylmethylsulphonyl fluoride (PMSF) and proteinase inhibitor cocktail (1 × ; Sigma, Dorset, U.K.)), sonicated and centrifuged. Protein concentrations of the resultant supernatants were determined using the BioRad protein assay (BioRad, U.K.). Cell lysates (30 <span class="i">μ</span>g protein per lane) were separated on 10% SDS–polyacrylamide gels and transferred to polyvinylidenedifluoride (PVDF) membranes (Hybond-P; Amersham, U.K.). Nonspecific protein binding was blocked using 2% ECL advanced blocking reagent (Amersham, U.K.). Blots were incubated overnight with anti-PPAR<span class="i">γ</span> antibody (Santa Cruz; diluted 1 : 1000) or anti-PPAR<span class="i">α</span> antibody (Santa Cruz; diluted 1 : 1000), followed by horseradish-peroxidase-conjugated goat anti-rabbit total IgG (Dako; diluted 1 : 2000) for 2 h. Immunoreactive bands were visualised using an enhanced chemiluminescence (ECL) detection kit (Amersham) according to the manufacturer's instructions and images captured using a BioRad FX-Imaging system.</p></div>
<a class="invisible-anchor" name="ss2-3">&nbsp;</a>
<div class="subsection-level2" id="ss2-3">
<a class="invisible-anchor" name="h6">&nbsp;</a>
<h2 id="h6" class="h2-heading">MTT cell survival studies</h2>
<p class="para">Rosiglitazone and GW9662 were purchased from Cayman Chemicals (St Louis, MO, U.S.A.). Cells (MCF7, MDA-MB-231, MDA-MB-468) were plated in 96-well plates at a density of 1 × 10<sup><nobr>3</nobr></sup> cells per well in RPMI medium. After overnight incubation to allow for cell attachment, the medium was removed and replaced with fresh medium containing varying concentrations of rosiglitazone (1–100 <span class="i">μ</span><span class="smallcapitals">M</span>), GW9662 (100 n<span class="smallcapitals">M</span>-50 <span class="i">μ</span><span class="smallcapitals">M</span>) or solvent (dimethyl sulphoxide (DMSO)) alone. MDA-MB-231 cells were also subjected to combinations of rosiglitazone (10, 50 <span class="i">μ</span><span class="smallcapitals">M</span>) and GW9662 (1, 10 <span class="i">μ</span><span class="smallcapitals">M</span>) added simultaneously. The final concentration of DMSO in all cases did not exceed 0.1% and was not found to be cytotoxic in any of the cell lines tested at this concentration. Chemosensitivity was assessed following a continuous 72 h exposure using a standard 3-[4, 5-dimethylthiazolyl]-2,5-diphenyltetrazolium bromide (MTT) assay.</p></div>
<a class="invisible-anchor" name="ss2-4">&nbsp;</a>
<div class="subsection-level2" id="ss2-4">
<a class="invisible-anchor" name="h7">&nbsp;</a>
<h2 id="h7" class="h2-heading">Cell growth assay</h2>
<p class="para">MDA-MB-231 cells were seeded at a density of 1 × 10<sup><nobr>5</nobr></sup> cells per 25 cm<sup><nobr>3</nobr></sup> tissue culture flask. After 24 h (day 0), the growth medium was replaced with fresh medium containing rosiglitazone (50 <span class="i">μ</span><span class="smallcapitals">M</span>), GW9662 (10 <span class="i">μ</span><span class="smallcapitals">M</span>) or both together. Control flasks received 0.1% DMSO. Cells were harvested on days 0, 3, 5, 7, 10 for each treatment condition by trypsinisation, stained using trypan blue, and the total and viable number of cells per flask calculated using a haemocytometer.</p></div>
<a class="invisible-anchor" name="ss2-5">&nbsp;</a>
<div class="subsection-level2" id="ss2-5">
<a class="invisible-anchor" name="h8">&nbsp;</a>
<h2 id="h8" class="h2-heading">Preparation of nuclear extracts of treated cells for measurement of PPARγ and PPARα activity</h2>
<p class="para">Levels of PPAR<span class="i">γ</span> and <span class="i">α</span> activity following rosiglitazone (50 <span class="i">μ</span><span class="smallcapitals">M</span>), GW9662 (10 <span class="i">μ</span><span class="smallcapitals">M</span>) or combination treatment were measured in the nuclear fraction of MDA-MB-231 and MCF7 cells using the PPAR transfactor kit (BD Biosciences Clontech, U.K.) as described below. Cells were seeded at a density of 1 × 10<sup><nobr>6</nobr></sup> cells per 75 cm<sup><nobr>3</nobr></sup> tissue culture flask. After 24 h, culture medium was removed and replaced with fresh medium containing the appropriate treatment. Following 2, 4, 8, 24 h of treatment, nuclear extracts were isolated (five flasks per treatment condition) using a transfactor extraction kit (BD Biosciences Clontech, U.K.), as per the manufacturer's instructions. The protein concentrations of the resultant supernatants (nuclear extract) were determined using the BioRad protein assay (BioRad, U.K.).</p></div>
<a class="invisible-anchor" name="ss2-6">&nbsp;</a>
<div class="subsection-level2" id="ss2-6">
<a class="invisible-anchor" name="h9">&nbsp;</a>
<h2 id="h9" class="h2-heading">Quantitative measurement of PPARγ and PPARα activity</h2>
<p class="para">PPAR<span class="i">γ</span> and PPAR<span class="i">α</span> activity was assayed in nuclear extracts using the PPAR transfactor assay (BD Bioscienes Clontech, U.K.), following the manufacturer's instructions. Briefly, following blocking of nonspecific binding to the PPRE-coated wells, 50 <span class="i">μ</span>g of nuclear extract or positive control extract (supplied with the kit) was added to the appropriate wells and the plate incubated for 60 min at room temperature. Primary anti-PPAR<span class="i">γ</span> antibody or anti-PPAR<span class="i">α</span> antibody was added to each well and the plate incubated for 60 min. Secondary antibody (anti-rabbit IgG-HRP) was added to each well and incubated for 30 min. Colorimetric detection of bound antibody was performed by addition of TMB substrate, incubation at room temperature for 20 min, addition of sodium azide stop buffer and measurement of absorbance at 655 nm using a microplate reader.</p></div>
<a class="invisible-anchor" name="ss2-7">&nbsp;</a>
<div class="subsection-level2" id="ss2-7">
<a class="invisible-anchor" name="h10">&nbsp;</a>
<h2 id="h10" class="h2-heading">Statistical analyses</h2>
<p class="para">Statistical analyses were undertaken using the SPSS software package, version 11.0 (SPSS Inc., Chicago, IL, U.S.A.). Values represent mean±standard error (s.e.) of replicate experiments. Data were analysed by Student's <span class="i">t</span>-test for and the threshold for statistical significance was assigned at <span class="i">P</span>=0.05.</p></div></div>
<a class="invisible-anchor" name="ss3">&nbsp;</a>
<div class="subsection-level1" id="ss3">
<a class="invisible-anchor" name="h11">&nbsp;</a>
<h1 id="h11" class="h1-heading">Results</h1><table><tbody><tr><td><a href="#abstract"><img src="sec_up_small.gif" alt="Abstract" title="Abstract" border="0"></a></td><td><a href="#ss1"><img src="sec_up_small.gif" alt="Introduction" title="Introduction" border="0"></a></td><td><a href="#ss2"><img src="sec_up_small.gif" alt="Methods" title="Methods" border="0"></a></td><td><a href="#ss3"><img src="sec_here_small.gif" alt="Results" title="Results" border="0"></a></td><td><a href="#ss4"><img src="sec_down_small.gif" alt="Discussion" title="Discussion" border="0"></a></td><td><a href="#ss5"><img src="sec_down_small.gif" alt="" title="" border="0"></a></td><td><a href="#ss6"><img src="sec_down_small.gif" alt="References" title="References" border="0"></a></td></tr></tbody></table>
<a class="invisible-anchor" name="ss3-1">&nbsp;</a>
<div class="subsection-level2" id="ss3-1">
<a class="invisible-anchor" name="h12">&nbsp;</a>
<h2 id="h12" class="h2-heading">Effect of the PPARγ agonist rosiglitazone and PPARγ antagonist GW9662 on cell survival</h2>
<p class="para">All of the cell lines utilised in this study were found to express PPAR<span class="i">γ</span> protein (<a href="#f1">Figure 1</a>), in agreement with previous studies (<a href="#b8"><sup><nobr>Jiang <span class="i">et al</span>., 2003</nobr></sup></a>). In contrast, PPAR<span class="i">α</span> protein was detectable in both MDA-MB-231 and MDA-MB-468 cells, but not the MCF7 cell line (<a href="#f1">Figure 1</a>), a previously unreported observation. This expression profile was supportive of the use of these cells for this study. To investigate the consequence of activation or inhibition of PPAR<span class="i">γ</span> upon survival of breast cell lines, MCF7, MDA-MB-231 and MDA-MB-468 cells were subjected to various doses of rosiglitazone or GW9662 for 72 h and cell viability analysed by MTT assay. Response to rosiglitazone was similar for all the three cell lines, with an IC<sub><nobr>50</nobr></sub> of approximately 50 <span class="i">μ</span><span class="smallcapitals">M</span>. Although this concentration appears relatively high, it is in line with values observed with other PPAR<span class="i">γ</span> agonists in breast cell lines (<a href="#b4"><sup><nobr>Clay <span class="i">et al</span>., 2001</nobr></sup></a>; <a href="#b20"><sup><nobr>Yin <span class="i">et al</span>., 2001</nobr></sup></a>). GW9662 acts as a potent antagonist of PPAR<span class="i">γ</span> in both cell-free and cell-based assays by covalently modifying a cysteine residue in the ligand-binding site of PPAR<span class="i">γ</span> (<a href="#b10"><sup><nobr>Leesnitzer <span class="i">et al</span>., 2002</nobr></sup></a>). Since GW9662 does not induce PPAR<span class="i">γ</span>-mediated transcription (<a href="#b10"><sup><nobr>Leesnitzer <span class="i">et al</span>., 2002</nobr></sup></a>) and exogenously added PPAR<span class="i">γ</span> agonists were not added to the culture media in this study, no response to GW9662 was expected as measured by MTT assay. Surprisingly, all the three cell lines demonstrated comparable loss of viability in response to GW9662 (<a href="#f2">Figure 2</a>; IC<sub><nobr>50</nobr></sub> 20–30 <span class="i">μ</span><span class="smallcapitals">M</span>), suggesting either the existence of PPAR<span class="i">γ</span> agonistic properties of GW9662 or growth-inhibitory mechanisms independent of PPAR<span class="i">γ</span>. ER alpha and beta (ER<span class="i">α</span>, <span class="i">β</span>) have been shown to inhibit PPAR transactivation and exhibit signal crosstalk with PPAR<span class="i">γ</span> (<a href="#b19"><sup><nobr>Wang &amp; Kilgore, 2002</nobr></sup></a>). Therefore, to reduce complicating factors when evaluating the 'true' involvement of PPAR<span class="i">γ</span> activation in the growth-inhibitory response of rosiglitazone and GW9662, our subsequent studies focused primarily on the ER<span class="i">α</span>-negative and oestrogen nonresponsive MDA-MB-231 cell line.</p>
<a class="invisible-anchor" name="f1">&nbsp;</a>
<div class="figure" id="f1" align="center"><table border="0" width="85%"><tbody><tr><td align="left" valign="top" width="128"><a href="javascript:display_f1(0)"><img src="tf1" border="0"></a></td><td align="left"><div class="figure-legend">
<p class="legend-para">
<a class="invisible-anchor" name="f1_legend_span">&nbsp;</a><span id="f1_legend_span"><span class="number">Figure 1</span>Expression of PPAR<span class="i">γ</span> and PPAR<span class="i">α</span> protein in human breast cell lines. Each lane was loaded with 30 <span class="i">μ</span>g cell lysate. MB468: MDA-MB-468; MB231: MDA-MB-231.</span></p></div><span class="image-links">[<a href="javascript:display_f1(0)">Normal View</a> ]</span></td></tr></tbody></table></div>
<a class="invisible-anchor" name="f2">&nbsp;</a>
<div class="figure" id="f2" align="center"><table border="0" width="85%"><tbody><tr><td align="left" valign="top" width="128"><a href="javascript:display_f2(0)"><img src="tf2" border="0"></a></td><td align="left"><div class="figure-legend">
<p class="legend-para">
<a class="invisible-anchor" name="f2_legend_span">&nbsp;</a><span id="f2_legend_span"><span class="number">Figure 2</span>Effect of the PPAR<span class="i">γ</span> antagonist GW9662 on viability of human breast cell lines. MCF7, MDA-MB-468, MDA-MB-231 were treated with GW9662 (0.1–50 <span class="i">μ</span><span class="smallcapitals">M</span>) for 72 h, and cell viability measured by MTT assay. Results, expressed as % of solvent control, are the mean±s.e. from three separate experiments.</span></p></div><span class="image-links">[<a href="javascript:display_f2(0)">Normal View</a> ]</span></td></tr></tbody></table></div></div>
<a class="invisible-anchor" name="ss3-2">&nbsp;</a>
<div class="subsection-level2" id="ss3-2">
<a class="invisible-anchor" name="h13">&nbsp;</a>
<h2 id="h13" class="h2-heading">GW9662 does not prevent rosiglitazone-mediated growth suppression</h2>
<p class="para">The observation that GW9662 itself has growth-inhibitory properties prompted us to investigate the effect of GW9662 upon rosiglitazone-induced cell growth suppression (<a href="#f3">Figure 3</a>). As a consequence of GW9662 being a high-affinity selective PPAR<span class="i">γ</span> inhibitor capable of fully abrogating PPAR<span class="i">γ</span> activation and signalling (<a href="#b10"><sup><nobr>Leesnitzer <span class="i">et al</span>., 2002</nobr></sup></a>), GW9662 was expected to prevent rosiglitazone-mediated growth inhibition. Surprisingly, co-treatment of MDA-MB-231 cells with both rosiglitazone and GW9662 resulted in an additive effect upon cell survival rather than the predicted subtractive effects, as measured by MTT assay (<a href="#f3">Figure 3</a>). Analysis of the cellular growth kinetics of MDA-MB-231 cells in the presence of rosiglitazone and GW9662 further confirmed this observation, in that GW9662 did not prevent rosiglitazone-induced growth inhibition, but instead acted to enhance the effect of rosiglitazone (<a href="#f4">Figure 4</a>). Co-treatment with both 50 <span class="i">μ</span><span class="smallcapitals">M</span> rosiglitazone and 10 <span class="i">μ</span><span class="smallcapitals">M</span> GW9662 resulted in statistically lower viable cell numbers after 7 days when compared to treatment with either 50 <span class="i">μ</span><span class="smallcapitals">M</span> rosiglitazone (<span class="i">P</span>=0.001) or 10 <span class="i">μ</span><span class="smallcapitals">M</span> GW9662 (<span class="i">P</span>=0.01) alone. Our data also indicated that cells in the presence of rosiglitazone and GW9662 were reaching the plateau phase of growth earlier than that observed in control conditions (<a href="#f4">Figure 4</a>). Although the reason for this observation is currently unclear, it may suggest that the induction of cellular differentiation by PPAR<span class="i">γ</span> ligands, as reported previously (<a href="#b11"><sup><nobr>Mueller <span class="i">et al</span>., 1998</nobr></sup></a>), can occur independently of PPAR<span class="i">γ</span>.</p>
<a class="invisible-anchor" name="f3">&nbsp;</a>
<div class="figure" id="f3" align="center"><table border="0" width="85%"><tbody><tr><td align="left" valign="top" width="128"><a href="javascript:display_f3(0)"><img src="tf3" border="0"></a></td><td align="left"><div class="figure-legend">
<p class="legend-para">
<a class="invisible-anchor" name="f3_legend_span">&nbsp;</a><span id="f3_legend_span"><span class="number">Figure 3</span>Effect of co-treatment of the PPAR<span class="i">γ</span> antagonist GW9662 and the PPAR<span class="i">γ</span> agonist rosiglitazone on viability of MDA-MB-231 cells. Cells were treated with rosiglitazone (0, 10, 50 <span class="i">μ</span><span class="smallcapitals">M</span>) in the presence or absence of GW9662 (0, 1, 10 <span class="i">μ</span><span class="smallcapitals">M</span>) for 72 h and cell viability measured by MTT assay. Results, expressed as % of solvent control, are the mean±s.e. of three independent experiments. *<span class="i">P</span>&lt;0.01 vs solvent control; <sup><nobr>†</nobr></sup><span class="i">P</span>&lt;0.01 vs 50 <span class="i">μ</span><span class="smallcapitals">M</span> rosiglitazone.</span></p></div><span class="image-links">[<a href="javascript:display_f3(0)">Normal View</a> ]</span></td></tr></tbody></table></div>
<a class="invisible-anchor" name="f4">&nbsp;</a>
<div class="figure" id="f4" align="center"><table border="0" width="85%"><tbody><tr><td align="left" valign="top" width="128"><a href="javascript:display_f4(0)"><img src="tf4" border="0"></a></td><td align="left"><div class="figure-legend">
<p class="legend-para">
<a class="invisible-anchor" name="f4_legend_span">&nbsp;</a><span id="f4_legend_span"><span class="number">Figure 4</span>Effect of rosiglitazone and GW9662 on cell growth kinetics of MDA-MB-231 cells. Cells were treated with either 50 <span class="i">μ</span><span class="smallcapitals">M</span> rosiglitazone, 10 <span class="i">μ</span><span class="smallcapitals">M</span> GW9662, combination of rosiglitazone and GW9662 or solvent alone, and the total number of viable cells calculated by trypan blue exclusion over a 10-day period. Error bars are omitted for clarity.</span></p></div><span class="image-links">[<a href="javascript:display_f4(0)">Normal View</a> ]</span></td></tr></tbody></table></div></div>
<a class="invisible-anchor" name="ss3-3">&nbsp;</a>
<div class="subsection-level2" id="ss3-3">
<a class="invisible-anchor" name="h14">&nbsp;</a>
<h2 id="h14" class="h2-heading">PPARγ activation is not involved in growth suppression induced by rosiglitazone and GW9662</h2>
<p class="para">Since both rosiglitazone and GW9662 had been shown to inhibit cell survival and retard cell growth, it was important to determine whether these effects were dependent upon activation of the PPAR<span class="i">γ</span> receptor. Using a modified ELISA assay (<a href="#b18"><sup><nobr>Shen <span class="i">et al</span>., 2002</nobr></sup></a>), the degree of PPAR<span class="i">γ</span> activation was determined in parallel to the cell survival and growth study. As predicted, rosiglitazone (50 <span class="i">μ</span><span class="smallcapitals">M</span>) and GW9662 (10 <span class="i">μ</span><span class="smallcapitals">M</span>) treatment resulted in an induction and inhibition of PPAR<span class="i">γ</span> activation, respectively (<a href="#f5">Figure 5</a>). In contrast, no activation or inhibition of PPAR<span class="i">α</span> activity was detected with either rosiglitazone or GW9662 (data not shown), demonstrating that the observed effects were not due to perturbation of PPAR<span class="i">α</span> activation. Interestingly, levels of PPAR<span class="i">γ</span> activation in cells exposed to GW9662 alone were significantly lower than that observed in either the solvent or untreated controls (<a href="#f5">Figure 5</a>), suggesting a degree of background PPAR<span class="i">γ</span> activation. This background PPAR<span class="i">γ</span> activity is likely to be as a consequence of endogenous PPAR<span class="i">γ</span> agonists within the cell growth media, which also contains 10% fetal calf serum. Treatment of MDA-MB-231 cells with both rosiglitazone (50 <span class="i">μ</span><span class="smallcapitals">M</span>) and GW9662 (10 <span class="i">μ</span><span class="smallcapitals">M</span>) simultaneously did not result in activation of PPAR<span class="i">γ</span> (<a href="#f5">Figure 5</a>; <span class="i">P</span><img src="les.gif">0.01 compared to either treatment alone). In addition to the 4 h timepoint (<a href="#f5">Figure 5</a>), similar activity responses were observed at 2, 8 and 24 h post-treatment (data not shown) and in the MCF7 cell line (<a href="#f5">Figure 5</a>). Taken together, these data strongly suggest that PPAR<span class="i">γ</span> activation may not be involved in the inhibition of cell survival or cell growth.</p>
<a class="invisible-anchor" name="f5">&nbsp;</a>
<div class="figure" id="f5" align="center"><table border="0" width="85%"><tbody><tr><td align="left" valign="top" width="128"><a href="javascript:display_f5(0)"><img src="tf5" border="0"></a></td><td align="left"><div class="figure-legend">
<p class="legend-para">
<a class="invisible-anchor" name="f5_legend_span">&nbsp;</a><span id="f5_legend_span"><span class="number">Figure 5</span>Levels of PPAR<span class="i">γ</span> activation following treatment with rosiglitazone and/or GW9662. MDA-MB-231 (white bars) and MCF7 (black bars) cells were treated with rosiglitazone (50 <span class="i">μ</span><span class="smallcapitals">M</span>), GW9662 (10 <span class="i">μ</span><span class="smallcapitals">M</span>) or both for 4 h and the level of PPAR<span class="i">γ</span> activity measured by the PPAR<span class="i">γ</span> transfactor modified ELISA assay. Results are expressed as fold change in activity compared to solvent control. Results are the mean±s.e. of three experiments.</span></p></div><span class="image-links">[<a href="javascript:display_f5(0)">Normal View</a> ]</span></td></tr></tbody></table></div></div></div>
<a class="invisible-anchor" name="ss4">&nbsp;</a>
<div class="subsection-level1" id="ss4">
<a class="invisible-anchor" name="h15">&nbsp;</a>
<h1 id="h15" class="h1-heading">Discussion</h1><table><tbody><tr><td><a href="#abstract"><img src="sec_up_small.gif" alt="Abstract" title="Abstract" border="0"></a></td><td><a href="#ss1"><img src="sec_up_small.gif" alt="Introduction" title="Introduction" border="0"></a></td><td><a href="#ss2"><img src="sec_up_small.gif" alt="Methods" title="Methods" border="0"></a></td><td><a href="#ss3"><img src="sec_up_small.gif" alt="Results" title="Results" border="0"></a></td><td><a href="#ss4"><img src="sec_here_small.gif" alt="Discussion" title="Discussion" border="0"></a></td><td><a href="#ss5"><img src="sec_down_small.gif" alt="" title="" border="0"></a></td><td><a href="#ss6"><img src="sec_down_small.gif" alt="References" title="References" border="0"></a></td></tr></tbody></table>
<p class="para">PPAR<span class="i">γ</span> is central to cellular lipid metabolism and is activated by a diverse range of compounds including fatty acids, eicosinoids and insulin sensitisers (<a href="#b9"><sup><nobr>Kliewer <span class="i">et al</span>., 2001</nobr></sup></a>; <a href="#b7"><sup><nobr>Gill &amp; Roberts, 2003</nobr></sup></a>). As such, PPAR<span class="i">γ</span> has been identified as a therapeutic target for obesity, hypolipidaemia and diabetes (<a href="#b9"><sup><nobr>Kliewer <span class="i">et al</span>., 2001</nobr></sup></a>). More recently, based on both <span class="i">in vitro</span> and <span class="i">in vivo</span> studies, perturbation of PPAR<span class="i">γ</span> expression and activity has been suggested as a therapeutic strategy for several epithelial tumour types, including breast (<a href="#b5"><sup><nobr>Elstner <span class="i">et al</span>., 1998</nobr></sup></a>; <a href="#b16"><sup><nobr>Roberts-Thomson, 2000</nobr></sup></a>; <a href="#b17"><sup><nobr>Rubin <span class="i">et al</span>., 2000</nobr></sup></a>; <a href="#b14"><sup><nobr>Pighetti <span class="i">et al</span>., 2001</nobr></sup></a>; <a href="#b19"><sup><nobr>Wang &amp; Kilgore, 2002</nobr></sup></a>). Although this is an interesting concept and is supported by a large number of primarily <span class="i">in vitro</span> studies, the involvement of PPAR<span class="i">γ</span> activation and its subsequent signalling pathway in such cases is purely implied based on parallel observation in other cell systems, such as lipid metabolism, and molecular studies demonstrating drug–receptor interaction. Understanding the involvement and role of PPAR<span class="i">γ</span> in breast tumour growth inhibition has important implications for both interpreting the results of current clinical trials (<a href="#b2"><sup><nobr>Burstein <span class="i">et al</span>., 2003</nobr></sup></a>) and the pharmacology of such compounds.</p>
<p class="para">In our study, the PPAR<span class="i">γ</span> ligand rosiglitazone activated PPAR<span class="i">γ</span> (<a href="#f5">Figure 5</a>) and inhibited growth and survival of breast cell lines <span class="i">in vitro</span>, independently of their reported oestrogen receptor-<span class="i">α</span> status, supporting the proposed therapeutic potential of these compounds in breast cancer and suggesting the direct involvement of PPAR<span class="i">γ</span> in the process. Surprisingly, the selective and irreversible PPAR<span class="i">γ</span> antagonist GW9662 also inhibited cell growth and survival of all cell lines (<a href="#f2">Figure 2</a>), but in this case PPAR<span class="i">γ</span> activity was strongly inhibited (<a href="#f5">Figure 5</a>). These data demonstrated that GW9662, in addition to inhibition of PPAR<span class="i">γ</span> activity, prevented cell growth and survival independently of PPAR<span class="i">γ</span>. Controversially, treatment of cells with GW9662 did not prevent rosiglitazone-mediated growth inhibition as expected (<a href="#f3">Figures 3</a> and <a href="#f4">4</a>), but instead acted to further reduce cell survival and growth (<a href="#f3">Figure 3</a>). The level of PPAR<span class="i">γ</span> activity in this situation was between that observed for rosiglitazone and GW9662 alone, at a level similar to that of the controls (<a href="#f5">Figure 5</a>). This suggests that either growth inhibition induced by rosiglitazone occurs independently of PPAR<span class="i">γ</span> activation or that GW9662 inhibits a pathway secondary to that of rosiglitazone.</p>
<p class="para">The suggestion that PPAR<span class="i">γ</span> activation is not involved in inhibition of cell survival and growth induced by known PPAR<span class="i">γ</span> agonists is supported by a study using xenografted PPAR<span class="i">γ</span>-null embryonic stem cells in which inhibition of tumour growth by TZDs occurred independently of PPAR<span class="i">γ</span> (<a href="#b12"><sup><nobr>Palakurthi <span class="i">et al</span>., 2001</nobr></sup></a>). Furthermore, apoptosis induced by the PPAR<span class="i">γ</span> ligand 15-deoxy Δ<sup><nobr>12,14</nobr></sup>-prostaglandin J2 has also been shown to occur independently of PPAR<span class="i">γ</span> activation (<a href="#b3"><sup><nobr>Clay <span class="i">et al</span>., 2002</nobr></sup></a>). In glioma cells, inhibition of cell survival by PPAR<span class="i">γ</span> agonists occurred independently of PPAR<span class="i">γ</span> activity, and was suggested to be as a result of loss of mitochondrial membrane potential and production of reactive oxygen species (<a href="#b13"><sup><nobr>Perez-Ortiz <span class="i">et al</span>., 2004</nobr></sup></a>). This mechanism of PPAR<span class="i">γ</span>-independent inhibition of cell survival is further supported by a study addressing growth inhibition by the PPAR<span class="i">γ</span> antagonist bisphenol A diglycidyl ether (BADGE), which induced apoptosis mediated by Bax-dependent release of cytochrome <span class="i">c</span> (<a href="#b6"><sup><nobr>Fehlberg <span class="i">et al</span>., 2003</nobr></sup></a>). Although further studies are required, our results in breast cell lines and those in other cell types (<a href="#b12"><sup><nobr>Palakurthi <span class="i">et al</span>., 2001</nobr></sup></a>; <a href="#b3"><sup><nobr>Clay <span class="i">et al</span>., 2002</nobr></sup></a>; <a href="#b6"><sup><nobr>Fehlberg <span class="i">et al</span>., 2003</nobr></sup></a>; <a href="#b13"><sup><nobr>Perez-Ortiz <span class="i">et al</span>., 2004</nobr></sup></a>) suggest that the central belief that PPAR<span class="i">γ</span> ligands, especially the thiazolidinediones, mediate their anticancer effects <span class="i">via</span> activation of the PPAR<span class="i">γ</span> receptor is questionable. The recent observations that PPAR<span class="i">γ</span> ligands can perturb mitochondrial membrane potential (<a href="#b13"><sup><nobr>Perez-Ortiz <span class="i">et al</span>., 2004</nobr></sup></a>), alter intracellular calcium storage (<a href="#b12"><sup><nobr>Palakurthi <span class="i">et al</span>., 2001</nobr></sup></a>) and effect release of apoptotic factors from the mitochondria (<a href="#b3"><sup><nobr>Clay <span class="i">et al</span>., 2002</nobr></sup></a>; <a href="#b6"><sup><nobr>Fehlberg <span class="i">et al</span>., 2003</nobr></sup></a>) suggest the existence of an alternative pathway for the anticancer effects of PPAR<span class="i">γ</span> ligands and a potential novel target for the development of anticancer therapeutics.</p></div></div>
<a class="invisible-anchor" name="s2">&nbsp;</a>
<div class="backmatter" id="s2">
<a class="invisible-anchor" name="ss5">&nbsp;</a>
<div class="subsection-level1" id="ss5">
<p class="para">We thank members of the Tom Connors Cancer Research Centre for technical help with this study. This work was supported by Cancer Research UK (grant number C459/A2579) and The Breast Cancer Campaign (grant number 2001:231).</p></div>
<a class="invisible-anchor" name="ss6">&nbsp;</a>
<div class="references" id="references">

<a class="invisible-anchor" name="h16">&nbsp;</a>
<h1 id="h16" class="h1-heading">References</h1><table><tbody><tr><td><a href="#abstract"><img src="sec_up_small.gif" alt="Abstract" title="Abstract" border="0"></a></td><td><a href="#ss1"><img src="sec_up_small.gif" alt="Introduction" title="Introduction" border="0"></a></td><td><a href="#ss2"><img src="sec_up_small.gif" alt="Methods" title="Methods" border="0"></a></td><td><a href="#ss3"><img src="sec_up_small.gif" alt="Results" title="Results" border="0"></a></td><td><a href="#ss4"><img src="sec_up_small.gif" alt="Discussion" title="Discussion" border="0"></a></td><td><a href="#ss5"><img src="sec_up_small.gif" alt="" title="" border="0"></a></td><td><a href="#ss6"><img src="sec_here_small.gif" alt="References" title="References" border="0"></a></td></tr></tbody></table>
<ul class="references-list">
<li><p class="reference-list-para" id="b1">
<a class="invisible-anchor" name="b1">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">AGARWAL</span>, <span class="forenames">V.R.</span></span>, <span class="name"><span class="surname">BISCHOFF</span>, <span class="forenames">E.D.</span></span>, <span class="name"><span class="surname">HERMANN</span>, <span class="forenames">T.</span></span> &amp; <span class="name"><span class="surname">LAMPH</span>, <span class="forenames">W.W.</span></span><span class="addresses"></span></span> (<span class="reference-date">2000</span>). <span class="reference-document-title">Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin)</span>. <span class="reference-journal-title">Cancer Res.</span>, <span class="reference-volume">60</span>, <span class="reference-page">6033</span>–<span class="reference-page">6038</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D1%26SNM%3DAGARWAL%26SNM%3DBISCHOFF%26SNM%3DHERMANN%26SNM%3DLAMPH%26FNM%3DV.R.%26FNM%3DE.D.%26FNM%3DT.%26FNM%3DW.W.%26ATL%3DInduction%20of%20adipocyte-specific%20gene%20expression%20is%20correlated%20with%20mammary%20tumor%20regression%20by%20the%20retinoid%20X%20receptor-ligand%20LGD1069%20%28targretin%29%26JTL%3DCancer%20Res.%26PYR%3D2000%26VID%3D60%26PPF%3D6033%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b2">
<a class="invisible-anchor" name="b2">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">BURSTEIN</span>, <span class="forenames">H.J.</span></span>, <span class="name"><span class="surname">DEMETRI</span>, <span class="forenames">G.D.</span></span>, <span class="name"><span class="surname">MUELLER</span>, <span class="forenames">E.</span></span>, <span class="name"><span class="surname">SARRAF</span>, <span class="forenames">P.</span></span>, <span class="name"><span class="surname">SPIEGELMAN</span>, <span class="forenames">B.M.</span></span> &amp; <span class="name"><span class="surname">WINER</span>, <span class="forenames">E.P.</span></span><span class="addresses"></span></span> (<span class="reference-date">2003</span>). <span class="reference-document-title">Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study</span>. <span class="reference-journal-title">Breast Cancer Res. Treat.</span>, <span class="reference-volume">79</span>, <span class="reference-page">391</span>–<span class="reference-page">397</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D2_2%26SNM%3DBURSTEIN%26SNM%3DDEMETRI%26SNM%3DMUELLER%26SNM%3DSARRAF%26SNM%3DSPIEGELMAN%26SNM%3DWINER%26FNM%3DH.J.%26FNM%3DG.D.%26FNM%3DE.%26FNM%3DP.%26FNM%3DB.M.%26FNM%3DE.P.%26ATL%3DUse%20of%20the%20peroxisome%20proliferator-activated%20receptor%20%28PPAR%29%20gamma%20ligand%20troglitazone%20as%20treatment%20for%20refractory%20breast%20cancer%3A%20a%20phase%20II%20study%26JTL%3DBreast%20Cancer%20Res.%20Treat.%26PYR%3D2003%26VID%3D79%26PPF%3D391%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b3">
<a class="invisible-anchor" name="b3">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">CLAY</span>, <span class="forenames">C.E.</span></span>, <span class="name"><span class="surname">MONJAZEB</span>, <span class="forenames">A.</span></span>, <span class="name"><span class="surname">THORBURN</span>, <span class="forenames">J.</span></span>, <span class="name"><span class="surname">CHILTON</span>, <span class="forenames">F.H.</span></span> &amp; <span class="name"><span class="surname">HIGH</span>, <span class="forenames">K.P.</span></span><span class="addresses"></span></span> (<span class="reference-date">2002</span>). <span class="reference-document-title">15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells</span>. <span class="reference-journal-title">J. Lipid Res.</span>, <span class="reference-volume">43</span>, <span class="reference-page">1818</span>–<span class="reference-page">1828</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D3_3%26SNM%3DCLAY%26SNM%3DMONJAZEB%26SNM%3DTHORBURN%26SNM%3DCHILTON%26SNM%3DHIGH%26FNM%3DC.E.%26FNM%3DA.%26FNM%3DJ.%26FNM%3DF.H.%26FNM%3DK.P.%26ATL%3D15-Deoxy-delta12%2C14-prostaglandin%20J2-induced%20apoptosis%20does%20not%20require%20PPARgamma%20in%20breast%20cancer%20cells%26JTL%3DJ.%20Lipid%20Res.%26PYR%3D2002%26VID%3D43%26PPF%3D1818%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b4">
<a class="invisible-anchor" name="b4">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">CLAY</span>, <span class="forenames">C.E.</span></span>, <span class="name"><span class="surname">NAMEN</span>, <span class="forenames">A.M.</span></span>, <span class="name"><span class="surname">ATSUMI</span>, <span class="forenames">G.</span></span>, <span class="name"><span class="surname">TRIMBOLI</span>, <span class="forenames">A.J.</span></span>, <span class="name"><span class="surname">FONTEH</span>, <span class="forenames">A.N.</span></span>, <span class="name"><span class="surname">HIGH</span>, <span class="forenames">K.P.</span></span> &amp; <span class="name"><span class="surname">CHILTON</span>, <span class="forenames">F.H.</span></span><span class="addresses"></span></span> (<span class="reference-date">2001</span>). <span class="reference-document-title">Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells</span>. <span class="reference-journal-title">J. Investig. Med.</span>, <span class="reference-volume">49</span>, <span class="reference-page">413</span>–<span class="reference-page">420</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D4_4%26SNM%3DCLAY%26SNM%3DNAMEN%26SNM%3DATSUMI%26SNM%3DTRIMBOLI%26SNM%3DFONTEH%26SNM%3DHIGH%26SNM%3DCHILTON%26FNM%3DC.E.%26FNM%3DA.M.%26FNM%3DG.%26FNM%3DA.J.%26FNM%3DA.N.%26FNM%3DK.P.%26FNM%3DF.H.%26ATL%3DMagnitude%20of%20peroxisome%20proliferator-activated%20receptor-gamma%20activation%20is%20associated%20with%20important%20and%20seemingly%20opposite%20biological%20responses%20in%20breast%20cancer%20cells%26JTL%3DJ.%20Investig.%20Med.%26PYR%3D2001%26VID%3D49%26PPF%3D413%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b5">
<a class="invisible-anchor" name="b5">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">ELSTNER</span>, <span class="forenames">E.</span></span>, <span class="name"><span class="surname">MULLER</span>, <span class="forenames">C.</span></span>, <span class="name"><span class="surname">KOSHIZUKA</span>, <span class="forenames">K.</span></span>, <span class="name"><span class="surname">WILLIAMSON</span>, <span class="forenames">E.</span></span>, <span class="name"><span class="surname">PARK</span>, <span class="forenames">D.</span></span>, <span class="name"><span class="surname">ASOU</span>, <span class="forenames">H.</span></span>, <span class="name"><span class="surname">SHINTAKU</span>, <span class="forenames">P.</span></span>, <span class="name"><span class="surname">SAID</span>, <span class="forenames">J.</span></span>, <span class="name"><span class="surname">HEBER</span>, <span class="forenames">D.</span></span> &amp; <span class="name"><span class="surname">HP</span>, <span class="forenames">K.</span></span><span class="addresses"></span></span> (<span class="reference-date">1998</span>). <span class="reference-document-title">Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells <span class="i">in vitro</span> and in BNX mice</span>. <span class="reference-journal-title">Proc. Natl. Acad. Sci. U.S.A.</span>, <span class="reference-volume">95</span>, <span class="reference-page">8806</span>–<span class="reference-page">8811</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D5_5%26SNM%3DELSTNER%26SNM%3DMULLER%26SNM%3DKOSHIZUKA%26SNM%3DWILLIAMSON%26SNM%3DPARK%26SNM%3DASOU%26SNM%3DSHINTAKU%26SNM%3DSAID%26SNM%3DHEBER%26SNM%3DHP%26FNM%3DE.%26FNM%3DC.%26FNM%3DK.%26FNM%3DE.%26FNM%3DD.%26FNM%3DH.%26FNM%3DP.%26FNM%3DJ.%26FNM%3DD.%26FNM%3DK.%26ATL%3DLigands%20for%20peroxisome%20proliferator-activated%20receptorgamma%20and%20retinoic%20acid%20receptor%20inhibit%20growth%20and%20induce%20apoptosis%20of%20human%20breast%20cancer%20cells%20in%20vitro%20and%20in%20BNX%20mice%26JTL%3DProc.%20Natl.%20Acad.%20Sci.%20U.S.A.%26PYR%3D1998%26VID%3D95%26PPF%3D8806%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b6">
<a class="invisible-anchor" name="b6">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">FEHLBERG</span>, <span class="forenames">S.</span></span>, <span class="name"><span class="surname">GREGEL</span>, <span class="forenames">C.M.</span></span>, <span class="name"><span class="surname">GOKE</span>, <span class="forenames">A.</span></span> &amp; <span class="name"><span class="surname">GOKE</span>, <span class="forenames">R.</span></span><span class="addresses"></span></span> (<span class="reference-date">2003</span>). <span class="reference-document-title">Bisphenol A diglycidyl ether-induced apoptosis involves Bax/Bid-dependent mitochondrial release of apoptosis-inducing factor (AIF), cytochrome <span class="i">c</span> and Smac/DIABLO</span>. <span class="reference-journal-title">Br. J. Pharmacol.</span>, <span class="reference-volume">139</span>, <span class="reference-page">495</span>–<span class="reference-page">500</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D6_6%26SNM%3DFEHLBERG%26SNM%3DGREGEL%26SNM%3DGOKE%26SNM%3DGOKE%26FNM%3DS.%26FNM%3DC.M.%26FNM%3DA.%26FNM%3DR.%26ATL%3DBisphenol%20A%20diglycidyl%20ether-induced%20apoptosis%20involves%20Bax%20Bid-dependent%20mitochondrial%20release%20of%20apoptosis-inducing%20factor%20%28AIF%29%2C%20cytochrome%20c%20and%20Smac%20DIABLO%26JTL%3DBr.%20J.%20Pharmacol.%26PYR%3D2003%26VID%3D139%26PPF%3D495%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b7">
<a class="invisible-anchor" name="b7">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">GILL</span>, <span class="forenames">J.</span></span> &amp; <span class="name"><span class="surname">ROBERTS</span>, <span class="forenames">R.</span></span><span class="addresses"></span></span> (<span class="reference-date">2003</span>). <span class="reference-document-title">PPARs and cancer</span>. <span class="reference-miscellaneoustext">In</span>: <span class="reference-book-title">Protein–Fatty Acid Interactions in the Mammalian Cell</span>, <span class="reference-miscellaneoustext">ed. Dutta-Roy, A. &amp; Spener, F</span>. <span class="reference-address"><span class="city">New York</span></span>: <span class="reference-publisher">VCH-Wiley</span>.</p></li>
<li><p class="reference-list-para" id="b8">
<a class="invisible-anchor" name="b8">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">JIANG</span>, <span class="forenames">W.G.</span></span>, <span class="name"><span class="surname">DOUGLAS-JONES</span>, <span class="forenames">A.</span></span> &amp; <span class="name"><span class="surname">MANSEL</span>, <span class="forenames">R.E.</span></span><span class="addresses"></span></span> (<span class="reference-date">2003</span>). <span class="reference-document-title">Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes</span>. <span class="reference-journal-title">Int. J. Cancer</span>, <span class="reference-volume">106</span>, <span class="reference-page">752</span>–<span class="reference-page">757</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D8_7%26SNM%3DJIANG%26SNM%3DDOUGLAS-JONES%26SNM%3DMANSEL%26FNM%3DW.G.%26FNM%3DA.%26FNM%3DR.E.%26ATL%3DExpression%20of%20peroxisome-proliferator%20activated%20receptor-gamma%20%28PPARgamma%29%20and%20the%20PPARgamma%20co-activator%2C%20PGC-1%2C%20in%20human%20breast%20cancer%20correlates%20with%20clinical%20outcomes%26JTL%3DInt.%20J.%20Cancer%26PYR%3D2003%26VID%3D106%26PPF%3D752%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b9">
<a class="invisible-anchor" name="b9">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">KLIEWER</span>, <span class="forenames">S.A.</span></span>, <span class="name"><span class="surname">XU</span>, <span class="forenames">H.E.</span></span>, <span class="name"><span class="surname">LAMBERT</span>, <span class="forenames">M.H.</span></span> &amp; <span class="name"><span class="surname">WILLSON</span>, <span class="forenames">T.M.</span></span><span class="addresses"></span></span> (<span class="reference-date">2001</span>). <span class="reference-document-title">Peroxisome proliferator-activated receptors: from genes to physiology</span>. <span class="reference-journal-title">Recent Progr. Hormone Res.</span>, <span class="reference-volume">56</span>, <span class="reference-page">239</span>–<span class="reference-page">263</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D9_8%26SNM%3DKLIEWER%26SNM%3DXU%26SNM%3DLAMBERT%26SNM%3DWILLSON%26FNM%3DS.A.%26FNM%3DH.E.%26FNM%3DM.H.%26FNM%3DT.M.%26ATL%3DPeroxisome%20proliferator-activated%20receptors%3A%20from%20genes%20to%20physiology%26JTL%3DRecent%20Progr.%20Hormone%20Res.%26PYR%3D2001%26VID%3D56%26PPF%3D239%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b10">
<a class="invisible-anchor" name="b10">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">LEESNITZER</span>, <span class="forenames">L.M.</span></span>, <span class="name"><span class="surname">PARKS</span>, <span class="forenames">D.J.</span></span>, <span class="name"><span class="surname">BLEDSOE</span>, <span class="forenames">R.K.</span></span>, <span class="name"><span class="surname">COBB</span>, <span class="forenames">J.E.</span></span>, <span class="name"><span class="surname">COLLINS</span>, <span class="forenames">J.L.</span></span>, <span class="name"><span class="surname">CONSLER</span>, <span class="forenames">T.G.</span></span>, <span class="name"><span class="surname">DAVIS</span>, <span class="forenames">R.G.</span></span>, <span class="name"><span class="surname">HULL-RYDE</span>, <span class="forenames">E.A.</span></span>, <span class="name"><span class="surname">LENHARD</span>, <span class="forenames">J.M.</span></span>, <span class="name"><span class="surname">PATEL</span>, <span class="forenames">L.</span></span>, <span class="name"><span class="surname">PLUNKET</span>, <span class="forenames">K.D.</span></span>, <span class="name"><span class="surname">SHENK</span>, <span class="forenames">J.L.</span></span>, <span class="name"><span class="surname">STIMMEL</span>, <span class="forenames">J.B.</span></span>, <span class="name"><span class="surname">THERAPONTOS</span>, <span class="forenames">C.</span></span>, <span class="name"><span class="surname">WILLSON</span>, <span class="forenames">T.M.</span></span> &amp; <span class="name"><span class="surname">BLANCHARD</span>, <span class="forenames">S.G.</span></span><span class="addresses"></span></span> (<span class="reference-date">2002</span>). <span class="reference-document-title">Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662</span>. <span class="reference-journal-title">Biochemistry</span>, <span class="reference-volume">41</span>, <span class="reference-page">6640</span>–<span class="reference-page">6650</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D10_9%26SNM%3DLEESNITZER%26SNM%3DPARKS%26SNM%3DBLEDSOE%26SNM%3DCOBB%26SNM%3DCOLLINS%26SNM%3DCONSLER%26SNM%3DDAVIS%26SNM%3DHULL-RYDE%26SNM%3DLENHARD%26SNM%3DPATEL%26SNM%3DPLUNKET%26SNM%3DSHENK%26SNM%3DSTIMMEL%26SNM%3DTHERAPONTOS%26SNM%3DWILLSON%26SNM%3DBLANCHARD%26FNM%3DL.M.%26FNM%3DD.J.%26FNM%3DR.K.%26FNM%3DJ.E.%26FNM%3DJ.L.%26FNM%3DT.G.%26FNM%3DR.G.%26FNM%3DE.A.%26FNM%3DJ.M.%26FNM%3DL.%26FNM%3DK.D.%26FNM%3DJ.L.%26FNM%3DJ.B.%26FNM%3DC.%26FNM%3DT.M.%26FNM%3DS.G.%26ATL%3DFunctional%20consequences%20of%20cysteine%20modification%20in%20the%20ligand%20binding%20sites%20of%20peroxisome%20proliferator%20activated%20receptors%20by%20GW9662%26JTL%3DBiochemistry%26PYR%3D2002%26VID%3D41%26PPF%3D6640%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b11">
<a class="invisible-anchor" name="b11">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">MUELLER</span>, <span class="forenames">E.</span></span>, <span class="name"><span class="surname">SARRAF</span>, <span class="forenames">P.</span></span>, <span class="name"><span class="surname">TONTONOZ</span>, <span class="forenames">P.</span></span>, <span class="name"><span class="surname">EVANS</span>, <span class="forenames">R.M.</span></span>, <span class="name"><span class="surname">MARTIN</span>, <span class="forenames">K.J.</span></span>, <span class="name"><span class="surname">ZHANG</span>, <span class="forenames">M.</span></span>, <span class="name"><span class="surname">FLETCHER</span>, <span class="forenames">C.</span></span>, <span class="name"><span class="surname">SINGER</span>, <span class="forenames">S.</span></span> &amp; <span class="name"><span class="surname">SPIEGELMAN</span>, <span class="forenames">B.M.</span></span><span class="addresses"></span></span> (<span class="reference-date">1998</span>). <span class="reference-document-title">Terminal differentiation of human breast cancer through PPAR gamma</span>. <span class="reference-journal-title">Mol. Cell</span>, <span class="reference-volume">1</span>, <span class="reference-page">465</span>–<span class="reference-page">470</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D11_10%26SNM%3DMUELLER%26SNM%3DSARRAF%26SNM%3DTONTONOZ%26SNM%3DEVANS%26SNM%3DMARTIN%26SNM%3DZHANG%26SNM%3DFLETCHER%26SNM%3DSINGER%26SNM%3DSPIEGELMAN%26FNM%3DE.%26FNM%3DP.%26FNM%3DP.%26FNM%3DR.M.%26FNM%3DK.J.%26FNM%3DM.%26FNM%3DC.%26FNM%3DS.%26FNM%3DB.M.%26ATL%3DTerminal%20differentiation%20of%20human%20breast%20cancer%20through%20PPAR%20gamma%26JTL%3DMol.%20Cell%26PYR%3D1998%26VID%3D1%26PPF%3D465%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b12">
<a class="invisible-anchor" name="b12">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">PALAKURTHI</span>, <span class="forenames">S.</span></span>, <span class="name"><span class="surname">AKTAS</span>, <span class="forenames">H.</span></span>, <span class="name"><span class="surname">GRUBISSICH</span>, <span class="forenames">L.</span></span>, <span class="name"><span class="surname">MORTENSEN</span>, <span class="forenames">R.</span></span> &amp; <span class="name"><span class="surname">HALPERIN</span>, <span class="forenames">J.</span></span><span class="addresses"></span></span> (<span class="reference-date">2001</span>). <span class="reference-document-title">Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation</span>. <span class="reference-journal-title">Cancer Res.</span>, <span class="reference-volume">61</span>, <span class="reference-page">6213</span>–<span class="reference-page">6218</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D12_11%26SNM%3DPALAKURTHI%26SNM%3DAKTAS%26SNM%3DGRUBISSICH%26SNM%3DMORTENSEN%26SNM%3DHALPERIN%26FNM%3DS.%26FNM%3DH.%26FNM%3DL.%26FNM%3DR.%26FNM%3DJ.%26ATL%3DAnticancer%20effects%20of%20thiazolidinediones%20are%20independent%20of%20peroxisome%20proliferator-activated%20receptor%20gamma%20and%20mediated%20by%20inhibition%20of%20translation%20initiation%26JTL%3DCancer%20Res.%26PYR%3D2001%26VID%3D61%26PPF%3D6213%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b13">
<a class="invisible-anchor" name="b13">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">PEREZ-ORTIZ</span>, <span class="forenames">J.M.</span></span>, <span class="name"><span class="surname">TRANQUE</span>, <span class="forenames">P.</span></span>, <span class="name"><span class="surname">VAQUERO</span>, <span class="forenames">C.F.</span></span>, <span class="name"><span class="surname">DOMINGO</span>, <span class="forenames">B.</span></span>, <span class="name"><span class="surname">MOLINA</span>, <span class="forenames">F.</span></span>, <span class="name"><span class="surname">CALVO</span>, <span class="forenames">S.</span></span>, <span class="name"><span class="surname">JORDAN</span>, <span class="forenames">J.</span></span>, <span class="name"><span class="surname">CENA</span>, <span class="forenames">V.</span></span> &amp; <span class="name"><span class="surname">LLOPIS</span>, <span class="forenames">J.</span></span><span class="addresses"></span></span> (<span class="reference-date">2004</span>). <span class="reference-document-title">Glitazones differentially regulate primary astrocyte and glioma cell survival: involvement of ROS and PPARgamma</span>. <span class="reference-journal-title">J. Biol. Chem.</span>, <span class="reference-volume">279</span>, <span class="reference-page">8976</span>–<span class="reference-page">8985</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D13_12%26SNM%3DPEREZ-ORTIZ%26SNM%3DTRANQUE%26SNM%3DVAQUERO%26SNM%3DDOMINGO%26SNM%3DMOLINA%26SNM%3DCALVO%26SNM%3DJORDAN%26SNM%3DCENA%26SNM%3DLLOPIS%26FNM%3DJ.M.%26FNM%3DP.%26FNM%3DC.F.%26FNM%3DB.%26FNM%3DF.%26FNM%3DS.%26FNM%3DJ.%26FNM%3DV.%26FNM%3DJ.%26ATL%3DGlitazones%20differentially%20regulate%20primary%20astrocyte%20and%20glioma%20cell%20survival%3A%20involvement%20of%20ROS%20and%20PPARgamma%26JTL%3DJ.%20Biol.%20Chem.%26PYR%3D2004%26VID%3D279%26PPF%3D8976%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b14">
<a class="invisible-anchor" name="b14">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">PIGHETTI</span>, <span class="forenames">G.M.</span></span>, <span class="name"><span class="surname">NOVOSAD</span>, <span class="forenames">W.</span></span>, <span class="name"><span class="surname">NICHOLSON</span>, <span class="forenames">C.</span></span>, <span class="name"><span class="surname">HITT</span>, <span class="forenames">D.C.</span></span>, <span class="name"><span class="surname">HANSENS</span>, <span class="forenames">C.</span></span>, <span class="name"><span class="surname">HOLLINGSWORTH</span>, <span class="forenames">A.B.</span></span>, <span class="name"><span class="surname">LERNER</span>, <span class="forenames">M.L.</span></span>, <span class="name"><span class="surname">BRACKETT</span>, <span class="forenames">D.</span></span>, <span class="name"><span class="surname">LIGHTFOOT</span>, <span class="forenames">S.A.</span></span> &amp; <span class="name"><span class="surname">GIMBLE</span>, <span class="forenames">J.M.</span></span><span class="addresses"></span></span> (<span class="reference-date">2001</span>). <span class="reference-document-title">Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands</span>. <span class="reference-journal-title">Anticancer Res.</span>, <span class="reference-volume">21</span>, <span class="reference-page">825</span>–<span class="reference-page">829</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D14_13%26SNM%3DPIGHETTI%26SNM%3DNOVOSAD%26SNM%3DNICHOLSON%26SNM%3DHITT%26SNM%3DHANSENS%26SNM%3DHOLLINGSWORTH%26SNM%3DLERNER%26SNM%3DBRACKETT%26SNM%3DLIGHTFOOT%26SNM%3DGIMBLE%26FNM%3DG.M.%26FNM%3DW.%26FNM%3DC.%26FNM%3DD.C.%26FNM%3DC.%26FNM%3DA.B.%26FNM%3DM.L.%26FNM%3DD.%26FNM%3DS.A.%26FNM%3DJ.M.%26ATL%3DTherapeutic%20treatment%20of%20DMBA-induced%20mammary%20tumors%20with%20PPAR%20ligands%26JTL%3DAnticancer%20Res.%26PYR%3D2001%26VID%3D21%26PPF%3D825%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b15">
<a class="invisible-anchor" name="b15">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">QIN</span>, <span class="forenames">C.</span></span>, <span class="name"><span class="surname">BURGHARDT</span>, <span class="forenames">R.</span></span>, <span class="name"><span class="surname">SMITH</span>, <span class="forenames">R.</span></span>, <span class="name"><span class="surname">WORMKE</span>, <span class="forenames">M.</span></span>, <span class="name"><span class="surname">STEWART</span>, <span class="forenames">J.</span></span> &amp; <span class="name"><span class="surname">SAFE</span>, <span class="forenames">S.</span></span><span class="addresses"></span></span> (<span class="reference-date">2003</span>). <span class="reference-document-title">Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells</span>. <span class="reference-journal-title">Cancer Res.</span>, <span class="reference-volume">63</span>, <span class="reference-page">958</span>–<span class="reference-page">964</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D15_14%26SNM%3DQIN%26SNM%3DBURGHARDT%26SNM%3DSMITH%26SNM%3DWORMKE%26SNM%3DSTEWART%26SNM%3DSAFE%26FNM%3DC.%26FNM%3DR.%26FNM%3DR.%26FNM%3DM.%26FNM%3DJ.%26FNM%3DS.%26ATL%3DPeroxisome%20proliferator-activated%20receptor%20gamma%20agonists%20induce%20proteasome-dependent%20degradation%20of%20cyclin%20D1%20and%20estrogen%20receptor%20alpha%20in%20MCF-7%20breast%20cancer%20cells%26JTL%3DCancer%20Res.%26PYR%3D2003%26VID%3D63%26PPF%3D958%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b16">
<a class="invisible-anchor" name="b16">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">ROBERTS-THOMSON</span>, <span class="forenames">S.J.</span></span><span class="addresses"></span></span> (<span class="reference-date">2000</span>). <span class="reference-document-title">Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment</span>. <span class="reference-journal-title">Immunol. Cell Biol.</span>, <span class="reference-volume">78</span>, <span class="reference-page">436</span>–<span class="reference-page">441</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D16_15%26SNM%3DROBERTS-THOMSON%26FNM%3DS.J.%26ATL%3DPeroxisome%20proliferator-activated%20receptors%20in%20tumorigenesis%3A%20targets%20of%20tumour%20promotion%20and%20treatment%26JTL%3DImmunol.%20Cell%20Biol.%26PYR%3D2000%26VID%3D78%26PPF%3D436%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b17">
<a class="invisible-anchor" name="b17">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">RUBIN</span>, <span class="forenames">G.L.</span></span>, <span class="name"><span class="surname">ZHAO</span>, <span class="forenames">Y.</span></span>, <span class="name"><span class="surname">KALUS</span>, <span class="forenames">A.M.</span></span> &amp; <span class="name"><span class="surname">SIMPSON</span>, <span class="forenames">E.R.</span></span><span class="addresses"></span></span> (<span class="reference-date">2000</span>). <span class="reference-document-title">Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy</span>. <span class="reference-journal-title">Cancer Res.</span>, <span class="reference-volume">60</span>, <span class="reference-page">1604</span>–<span class="reference-page">1608</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D17_16%26SNM%3DRUBIN%26SNM%3DZHAO%26SNM%3DKALUS%26SNM%3DSIMPSON%26FNM%3DG.L.%26FNM%3DY.%26FNM%3DA.M.%26FNM%3DE.R.%26ATL%3DPeroxisome%20proliferator-activated%20receptor%20gamma%20ligands%20inhibit%20estrogen%20biosynthesis%20in%20human%20breast%20adipose%20tissue%3A%20possible%20implications%20for%20breast%20cancer%20therapy%26JTL%3DCancer%20Res.%26PYR%3D2000%26VID%3D60%26PPF%3D1604%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b18">
<a class="invisible-anchor" name="b18">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">SHEN</span>, <span class="forenames">Z.</span></span>, <span class="name"><span class="surname">PEEDIKAYIL</span>, <span class="forenames">J.</span></span>, <span class="name"><span class="surname">OLSON</span>, <span class="forenames">G.K.</span></span>, <span class="name"><span class="surname">SIEBERT</span>, <span class="forenames">P.D.</span></span> &amp; <span class="name"><span class="surname">FANG</span>, <span class="forenames">Y.</span></span><span class="addresses"></span></span> (<span class="reference-date">2002</span>). <span class="reference-document-title">Multiple transcription factor profiling by enzyme-linked immunoassay</span>. <span class="reference-journal-title">Biotechniques</span>, <span class="reference-volume">32</span>, <span class="reference-miscellaneoustext">1168</span> <span class="reference-page">1170</span>–<span class="reference-page">1172</span>, <span class="reference-miscellaneoustext">1174 passim</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D18_17%26SNM%3DSHEN%26SNM%3DPEEDIKAYIL%26SNM%3DOLSON%26SNM%3DSIEBERT%26SNM%3DFANG%26FNM%3DZ.%26FNM%3DJ.%26FNM%3DG.K.%26FNM%3DP.D.%26FNM%3DY.%26ATL%3DMultiple%20transcription%20factor%20profiling%20by%20enzyme-linked%20immunoassay%26JTL%3DBiotechniques%26PYR%3D2002%26VID%3D32%26PPF%3D1170%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b19">
<a class="invisible-anchor" name="b19">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">WANG</span>, <span class="forenames">X.</span></span> &amp; <span class="name"><span class="surname">KILGORE</span>, <span class="forenames">M.W.</span></span><span class="addresses"></span></span> (<span class="reference-date">2002</span>). <span class="reference-document-title">Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells</span>. <span class="reference-journal-title">Mol. Cell. Endocrinol.</span>, <span class="reference-volume">194</span>, <span class="reference-page">123</span>–<span class="reference-page">133</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D19_18%26SNM%3DWANG%26SNM%3DKILGORE%26FNM%3DX.%26FNM%3DM.W.%26ATL%3DSignal%20cross-talk%20between%20estrogen%20receptor%20alpha%20and%20beta%20and%20the%20peroxisome%20proliferator-activated%20receptor%20gamma1%20in%20MDA-MB-231%20and%20MCF-7%20breast%20cancer%20cells%26JTL%3DMol.%20Cell.%20Endocrinol.%26PYR%3D2002%26VID%3D194%26PPF%3D123%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li>
<li><p class="reference-list-para" id="b20">
<a class="invisible-anchor" name="b20">&nbsp;</a><span class="author-info"><span class="name"><span class="surname">YIN</span>, <span class="forenames">F.</span></span>, <span class="name"><span class="surname">WAKINO</span>, <span class="forenames">S.</span></span>, <span class="name"><span class="surname">LIU</span>, <span class="forenames">Z.</span></span>, <span class="name"><span class="surname">KIM</span>, <span class="forenames">S.</span></span>, <span class="name"><span class="surname">HSUEH</span>, <span class="forenames">W.A.</span></span>, <span class="name"><span class="surname">COLLINS</span>, <span class="forenames">A.R.</span></span>, <span class="name"><span class="surname">VAN HERLE</span>, <span class="forenames">A.J.</span></span> &amp; <span class="name"><span class="surname">LAW</span>, <span class="forenames">R.E.</span></span><span class="addresses"></span></span> (<span class="reference-date">2001</span>). <span class="reference-document-title">Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators</span>. <span class="reference-journal-title">Biochem. Biophys. Res. Commun.</span>, <span class="reference-volume">286</span>, <span class="reference-page">916</span>–<span class="reference-page">922</span>. <a href="http://www3.interscience.wiley.com.ejproxy.a-star.edu.sg/cgi-bin/reflink?object=TYPE%3DJCIT%26BIBID%3D20_19%26SNM%3DYIN%26SNM%3DWAKINO%26SNM%3DLIU%26SNM%3DKIM%26SNM%3DHSUEH%26SNM%3DCOLLINS%26SNM%3DVAN%20HERLE%26SNM%3DLAW%26FNM%3DF.%26FNM%3DS.%26FNM%3DZ.%26FNM%3DS.%26FNM%3DW.A.%26FNM%3DA.R.%26FNM%3DA.J.%26FNM%3DR.E.%26ATL%3DTroglitazone%20inhibits%20growth%20of%20MCF-7%20breast%20carcinoma%20cells%20by%20targeting%20G1%20cell%20cycle%20regulators%26JTL%3DBiochem.%20Biophys.%20Res.%20Commun.%26PYR%3D2001%26VID%3D286%26PPF%3D916%26ADOI%3D10.1038/sj.bjp.0705973%26EVIEW%3DY%26ENABLEISI%3DN%26ENABLECAS%3DY%26ENABLEPM%3DY" target="_top"><span style="color: rgb(51, 102, 153);">Links</span></a>&nbsp;&nbsp;</p></li></ul></div></div></div></div>

					</div>
				</td>
				<td width="10"><div class="spacer"><img src="dot.clear.gif" alt="" border="0" height="1" width="10"></div></td>
			</tr></tbody></table>
			<!-- END: prerendered content -->

		</div>
		<!-- END: content -->

	</div>
	<!-- END: main column -->

</div>

<!-- END: journal-article.html-main.tpl -->

<!-- END: ftx_abs.tpl -->
</body>
</html>
